Application of response surface methodology for optimization of oxytetracycline hydrochloride degradation using hydrogen peroxide/polystyrene-supported iron phthalocyanine oxidation process

Comparison of the degradation mechanisms of diclofenac in the presence of iron octacarboxyphthalocyanine and myeloperoxidase

The degradation process of diclofenac (DCF) by hematoprotein myeloperoxidase (MPO) and iron octacarboxyphthalocyanine (FePcOC) in the presence of hydrogen peroxide was compared. During the oxidation of diclofenac, in the presence of iron octacarboxyphthalocyanine (FePcOC) and hydroxyl radicals (HO^•) (from H₂O₂), an intermediate product (dimer with an m/z value of 587) with the characteristic yellow colouration and an intense band at λ_max = 451 nm is formed. Iron octacarboxyphthalocyanine oxidises in the presence of hydrogen peroxide, following the first-order reaction kinetics for FePcOC and H₂O₂. The concentration of diclofenac does not affect the initial reaction rate. For comparison, the oxidation of DCF in the presence of myeloperoxidase and hydrogen peroxide also provided yellow-coloured solutions with an absorption maximum at λ_max = 451 nm. However, LC-MS/MS analysis indicates the presence of at least seven main products of the diclofenac oxidation process in the final reaction mixture, including two dimers with the ion mass [M-H]^¯ = 587.01. The mechanism of the diclofenac degradation with hematoprotein myeloperoxidase is more complex than with iron octacarboxyphthalocyanine. Furthermore, the biological activity of diclofenac and DCF dimer (iron octacarboxyphthalocyanine and hydroxyl radicals degradation product) was tested. In this case, the long-term assayed in vitro against E. coli, colorectal HCT116 and melanoma Me45 cancer cells were performed.

Oxidative Degradation of Pharmaceuticals: The Role of Tetrapyrrole-Based Catalysts

Nowadays, society’s widespread consumption of pharmaceutical drugs and the consequent accumulation of such compounds or their metabolites in effluents requires the development of efficient strategies and systems that lead to their effective degradation. This can be done through oxidative processes, in which tetrapyrrolic macrocycles (porphyrins, phthalocyanines) deserve special attention since they are among the most promising degradation catalysts. This paper presents a review of the literature over the past ten years on the major advances made in the development of oxidation processes of pharmaceuticals in aqueous solutions using tetrapyrrole-based catalysts. The review presents a brief discussion of the mechanisms involved in these oxidative processes and is organized by the degradation of families of pharmaceutical compounds, namely antibiotics, analgesics and neurological drugs, among others. For each family, a critical analysis and discussion of the fundamental roles of tetrapyrrolic macrocycles are presented, regarding both photochemical degradative processes and direct oxidative chemical degradation.